Topographical distribution of neurochemical changes in Alzheimer's disease

Journal of the Neurological Sciences

Volumn 84, Issue 2-3, 1988, Pages 125-140

  Procter, Andrew W ^a,b   Lowe, Stephen L ^a   Palmer, Alan M ^a   Francis, Paul T ^a   Esiri, Margaret M ^c   Stratmann, Gary C ^a   Najlerahim, Adolrahman ^a   Patel, Ambrish J ^d   Hunt, Anthony ^d   Bowen, David M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c RADCLIFFE INFIRMARY   (United Kingdom)

^d MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Alzheimer's disease; Amino acid neurotransmitters; Cerebral atrophy; Choline acetyltransferase; Serotonin receptors

Indexed keywords

CHOLINE ACETYLTRANSFERASE; EXCITATORY AMINO ACID; GLUTAMINASE; RADIOISOTOPE; SEROTONIN RECEPTOR; SOMATOSTATIN;

ALZHEIMER DISEASE; AUTOPSY; BRAIN ATROPHY; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMINO ACIDS, DICARBOXYLIC; ASPARAGINE; ASPARTIC ACID; CEREBELLAR CORTEX; CEREBRAL CORTEX; CHOLINE O-ACETYLTRANSFERASE; GLUTAMATES; GLUTAMINASE; GLUTAMINE; HUMANS; MIDDLE AGED; SOMATOSTATIN;

EID: 0023838439     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0022-510X(88)90118-9     Document Type: Article

References (53)

1. Somatostatin and vasoactive intestinal polypeptide in post-mortem brains from patients with Alzheimer-type dementia
2. Widespread reduction of somatostatin-like immunoreactivity in the cerebral cortex in Alzheimer's disease
3. Biochemical assessment of neurotransmitter and metabolic dysfunction and cerebral atrophy in Alzheimer's disease
4. Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease
5. Neurotransmitter and metabolic dysfunction in Alzheimer's dementia: Relationship to histopathological features
6. (-)-Baclofen decreases neurotransmitter release in the mammalian CNS by an action at a novel GABA receptor
7. Ratio of pyramidal cell versus nonpyramidal cells in the human frontal cortex and changes in ratio with ageing and Alzheimer's disease
8. An overview of light and electron microscopic changes
9. Positron emission tomography in aging and dementia: effect of cerebral atrophy
10. Serotonin receptor changes in dementia of the Alzheimer's type
11. Studies on neurotransmitter receptor systems in neocortex and hippocampus in senile dementia of the Alzheimer-type
12. The selectivity of the reduction of serotonin S2 receptors in Alzheimer-type dementia
13. +-dependent “binding” of D-aspartate in brain membranes is largely due to uptake into membrane-bounded saccules
14. Choline acetyltransferase, somatostatin and substance P in selected cases of Alzheimer's disease
15. A post-mortem study of amino acid neurotransmitters in Alzheimer's disease
16. Somatostatin content and release measured in cerebral biopsies from demented patients
17. The dementia of Alzheimer's disease: an update
18. Glutamate: a neurotransmitter in mammalian brain
19. 3 pyramidal cells in hippocampal culture
20. Neuropathological aspects of brain aging and SDAT
21. Neurotransmitters in the cerebral cortex
22. Commissural and corticocortical “column” in the somatic sensory cortex of primates
23. Substrate mediated regulation of phosphate-activated glutaminase in nervous tissue
24. 3H-ligand for serotonin receptor binding sites
25. Gamma-aminobutyric acid concentration in brain tissue at two stages of Alzheimer's disease
26. 3H]TCP binding in Alzheimer's disease
27. Serotonin neurones and receptors in Alzheimer's disease
28. Regional weight loss of the cerebral cortex and some subcortical nuclei in senile dementia of the Alzheimer type
29. Alzheimer's disease: A correlative study
30. Excitatory amino acid-releasing and cholinergic neurones in Alzheimer's disease
31. Catecholaminergic neurones assessed antemortem in Alzheimer's disease
32. Effect of thyroid deficiency on the regional development of glutaminase, a glutamatergic neuron marker, in the rat brain
33. Neurotransmitter dysfunction and atrophy of the caudate nucleus in Alzheimer's disease
34. Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer's disease
35. Intralaminar neurochemical distributions in human midtemporal cortex: comparison between Alzheimer's disease and the normal
36. Cortical serotonin S2 receptor binding abnormalities in patients with Alzheimer's disease
37. Ageing in the cerebral neocortex and psychiatric disorder
38. Glutamate/aspartate-releasing neurons in Alzheimer's disease
39. Evidence of glutamatergic denervation and possible abnormal metabolism in Alzheimer's disease
40. 2 receptors in senile dementia of the Alzheimer type
41. Quantitative morphology and regional and laminar distributions of senile plaques in Alzheimer's disease
42. A postmortem study of the cholinergic and GABA systems in senile dementia
43. Regional distribution of amino acid transmitters in postmortem brains of presenile and senile dementia of Alzheimer type
44. 2 receptors in human brain
45. The evoked release of endogenous amino acids from tissue prisms of human neocortex
46. Amino acid release from biopsy samples of temporal neocortex from patients with Alzheimer's disease
47. Oral tetrahydroamino-acridine in long-term treatment of senile dementia, Alzheimer type
48. Phosphate activated glutaminase in the crude mitochondrial fraction (P2 fraction) from human brain cortex
49. Alzheimer's disease: low cerebral somatostatin levels correlate with impaired cognitive function and cortical metabolism
50. A comparison of sodium-dependent glutamate binding with high-affinity glutamate uptake in rat striatum
51. 3H]ketanserin binding increases in monkey cortex following basal forebrain lesions with lbotenic acid
52. Immunocytochemical localization of aspartate aminotransferase and glutaminase immunoreactivites in the cerebellum
53. Plaques, tangles and dementia